Oncolys BioPharma Inc. provided non-consolidated earnings guidance for the fiscal year ending December 31, 2022. For the period, the company expects net sales to be JPY 1,000 million, operating loss to be JPY 1,600 million, loss to be JPY 1,600 million and basic loss per share to be JPY 94.59.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
622 JPY | -4.16% | -10.25% | +9.70% |
1st Jan change | Capi. | |
---|---|---|
+9.70% | 86.8M | |
-3.15% | 89.69B | |
+2.50% | 41.34B | |
-12.59% | 33.72B | |
+62.74% | 26.11B | |
-20.67% | 14.63B | |
-9.06% | 12.84B | |
-12.34% | 11.66B | |
-43.92% | 11.52B | |
+4.27% | 8.92B |
- Stock Market
- Equities
- 4588 Stock
- News Oncolys BioPharma Inc.
- Oncolys Biopharma Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022